NewAmsterdam Pharma (NAMS) Projected to Post Quarterly Earnings on Wednesday

NewAmsterdam Pharma (NASDAQ:NAMS) is anticipated to issue its quarterly earnings data before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.48) per share for the quarter.

NewAmsterdam Pharma Stock Up 0.7 %

Shares of NASDAQ:NAMS opened at $20.04 on Wednesday. NewAmsterdam Pharma has a fifty-two week low of $15.19 and a fifty-two week high of $27.29. The firm has a 50-day simple moving average of $23.55 and a 200 day simple moving average of $20.18.

Analysts Set New Price Targets

NAMS has been the subject of several recent research reports. Scotiabank upped their target price on NewAmsterdam Pharma from $35.00 to $47.00 and gave the company a “sector outperform” rating in a report on Wednesday, December 11th. Needham & Company LLC reaffirmed a “buy” rating and issued a $36.00 target price on shares of NewAmsterdam Pharma in a research report on Thursday, December 5th. Royal Bank of Canada reissued an “outperform” rating and set a $40.00 price target on shares of NewAmsterdam Pharma in a report on Friday, January 24th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $48.00 price objective on shares of NewAmsterdam Pharma in a report on Tuesday, January 14th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, NewAmsterdam Pharma currently has a consensus rating of “Buy” and an average price target of $41.60.

Insider Buying and Selling at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, major shareholder Nap B.V. Forgrowth sold 166,011 shares of the firm’s stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $25.39, for a total transaction of $4,215,019.29. Following the transaction, the insider now owns 11,150,461 shares of the company’s stock, valued at approximately $283,110,204.79. This trade represents a 1.47 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold 404,927 shares of company stock valued at $10,390,787 in the last quarter. Corporate insiders own 19.50% of the company’s stock.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.